عنوان

Antiviral drugs

شابک

9780470455630 (cloth)

کد کشور

IR

شماره

E-6219

زبان متن نوشتاري يا گفتاري و مانند آن

انگلیسی

کشور محل نشر

IR

عنوان اصلي

Antiviral drugs

نام عام مواد

[Book]

ساير اطلاعات عنواني

:from basic discovery through clinical trials

نام نخستين پديدآور

/ edited by Wieslaw M. Kazmierski

محل نشرو پخش و غیره

Hoboken, N.J.

نام ناشر، پخش کننده و غيره

: Wiley,

تاریخ نشرو بخش و غیره

, c2011.

نام خاص و کميت اثر

xiii, 438 p., [16] p. of plates , ill. (some col.) , 29 cm.

متن يادداشت

Print

متن يادداشت

Includes bibliographical references and index.

متن يادداشت

Section VI. Protease Inhibitors: Discovery and development of telaprevir -- Discovery and development of BILN 2061 and follow-up BI 201335 -- Intervention of Hepatitis C replication through NS3-4A, the protease inhibitor boceprevir -- Discovery and development of the HCV NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) -- Discovery and development of the HCV protease inhibitor TMC435 -- Section VII. HCV Polymerase Nucleoside Inhibitors: Discovery and clinical evaluation of the nucleoside analog balapiravir (R1626) for the treatment of HCV infection -- Discovery and development of PSI-6130/RG7128 -- Section VIII. Other HCV Inhibitors: Discovery of Cyclophilin inhibitor NIM811 as a novel therapeutic agent for HCV -- HCV viral entry inhibitors -- Discovery of the RSV inhibitor TMC353121 -- Discovery and development of orally active RSV fusion inhibitors -- Discovery and development of RSV604 -- Discovery and development of influenza virus sialidase inhibitor relenza -- Discovery and development of entecavir -- Benzimidazole ribonucleosides: novel drug candidates for the prevention and treatment of cytomegalovirus diseases.

متن يادداشت

Section 1. HIV Protease Inhibitors: Discovery and development of atazanavir -- Discovery and development of PL-100, a novel HIV-1 protease inhibitor -- Darunavir (Prezista, TMC114): from bench to clinic, improving treatment options for HIV-infected patients -- Discovery and development of tipranavir -- Section II. HIV Non-nucleoside Reverse Transcriptase Inhibitors: TMC278 (Rilpivirine): a next-generation NNRTI in phase III clinical development for treatment-naive patients -- Entravirine: from TMC125 to intelence: a treatment paradigm shift for HIV-infected patients -- Section III. HIV Nucleoside Reverse Transcriptase Inhibitors: Discovery and development of tenovir disoproxil fumarate -- Discovery and development of apricitabine -- Section IV. HIV Entry Inhibitors: Discovery and development of maraviroc and PF-232798: CCR5 antagonists for the treatment of HIV-1 infection -- Discovery of the CCR5 antagonist vicriviroc (Sch 417690/Sch-D) for the treatment of HIV-1 infection -- Discovery and development of HIV-1 entry inhibitors that target gp120 -- Section V. HIV Integrase Inhibitors: Discovery of MK-0536: a potential second-generation HIV-1 integrase strand transfer inhibitor with a high genetic barrier to mutation -- Discovery and development of HIV integrase inhibitor raltegravir -- Elvitegravir: a novel monoketo acid HIV-1 integrase strand transfer inhibitor --

موضوع مستند نشده

Antiviral agents

موضوع مستند نشده

Antiviral Agents, therapeutic use

موضوع مستند نشده

Clinical Trials as Topic

موضوع مستند نشده

Drug Discovery

موضوع مستند نشده

Drug Evaluation

شماره

شماره رده

نشانه اثر

شماره رده

نشانه اثر

مستند نام اشخاص تاييد نشده

Kazmierski, Wieslaw M

کشور

ایران

وضعیت فهرست نویسی

old catalog

فرمت انتشار

p

نوع ماده

BL

پیشوند ISBD اعمال شده است

1

سطح دسترسي

a

تكميل شده

Y